These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 15808341)

  • 1. The efficiency of multi-target drugs: the network approach might help drug design.
    Csermely P; Agoston V; Pongor S
    Trends Pharmacol Sci; 2005 Apr; 26(4):178-82. PubMed ID: 15808341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to design multi-target drugs.
    Korcsmáros T; Szalay MS; Böde C; Kovács IA; Csermely P
    Expert Opin Drug Discov; 2007 Jun; 2(6):799-808. PubMed ID: 23488998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systems biology approaches and tools for analysis of interactomes and multi-target drugs.
    Schrattenholz A; Groebe K; Soskic V
    Methods Mol Biol; 2010; 662():29-58. PubMed ID: 20824465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledgebase for addiction-related genes: is it possible an extrapolation to rational multi-target drug design?
    Espinoza-Fonseca LM
    Bioorg Med Chem; 2008 Oct; 16(20):9346-8. PubMed ID: 18815048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragments, network biology and designing multiple ligands.
    Morphy R; Rankovic Z
    Drug Discov Today; 2007 Feb; 12(3-4):156-60. PubMed ID: 17275736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum.
    González-Díaz H; Prado-Prado F; Sobarzo-Sánchez E; Haddad M; Maurel Chevalley S; Valentin A; Quetin-Leclercq J; Dea-Ayuela MA; Teresa Gomez-Muños M; Munteanu CR; José Torres-Labandeira J; García-Mera X; Tapia RA; Ubeira FM
    J Theor Biol; 2011 May; 276(1):229-49. PubMed ID: 21277861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated approach for inference and mechanistic modeling for advancing drug development.
    Aksenov SV; Church B; Dhiman A; Georgieva A; Sarangapani R; Helmlinger G; Khalil IG
    FEBS Lett; 2005 Mar; 579(8):1878-83. PubMed ID: 15763567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mining metabolic networks for optimal drug targets.
    Sridhar P; Song B; Kahveci T; Ranka S
    Pac Symp Biocomput; 2008; ():291-302. PubMed ID: 18229694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds.
    Prado-Prado FJ; González-Díaz H; de la Vega OM; Ubeira FM; Chou KC
    Bioorg Med Chem; 2008 Jun; 16(11):5871-80. PubMed ID: 18485714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rational approach to maximize success rate in target discovery.
    Schneider M
    Arch Pharm (Weinheim); 2004 Dec; 337(12):625-33. PubMed ID: 15597396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-efficacy depends on the inhibitor type and the target position in a metabolic network--a systematic study.
    Gerber S; Assmus H; Bakker B; Klipp E
    J Theor Biol; 2008 Jun; 252(3):442-55. PubMed ID: 17981303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational drug design.
    Mandal S; Moudgil M; Mandal SK
    Eur J Pharmacol; 2009 Dec; 625(1-3):90-100. PubMed ID: 19835861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.